- Home
- LCNB vs DMAC Comparison
LCNB vs DMAC Comparison
Compare LCNB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCNB
- DMAC
- Stock Information
- Founded
- LCNB 1877
- DMAC 2000
- Country
- LCNB United States
- DMAC United States
- Employees
- LCNB N/A
- DMAC N/A
- Industry
- LCNB Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LCNB Finance
- DMAC Health Care
- Exchange
- LCNB Nasdaq
- DMAC Nasdaq
- Market Cap
- LCNB 212.3M
- DMAC 172.7M
- IPO Year
- LCNB N/A
- DMAC N/A
- Fundamental
- Price
- LCNB $16.89
- DMAC $4.18
- Analyst Decision
- LCNB
- DMAC Strong Buy
- Analyst Count
- LCNB 0
- DMAC 3
- Target Price
- LCNB N/A
- DMAC $7.00
- AVG Volume (30 Days)
- LCNB 22.3K
- DMAC 46.2K
- Earning Date
- LCNB 10-21-2024
- DMAC 11-13-2024
- Dividend Yield
- LCNB 5.13%
- DMAC N/A
- EPS Growth
- LCNB N/A
- DMAC N/A
- EPS
- LCNB 0.52
- DMAC N/A
- Revenue
- LCNB $74,686,000.00
- DMAC N/A
- Revenue This Year
- LCNB N/A
- DMAC N/A
- Revenue Next Year
- LCNB $15.49
- DMAC N/A
- P/E Ratio
- LCNB $32.96
- DMAC N/A
- Revenue Growth
- LCNB 3.03
- DMAC N/A
- 52 Week Low
- LCNB $12.42
- DMAC $2.14
- 52 Week High
- LCNB $17.27
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- LCNB 62.34
- DMAC 48.23
- Support Level
- LCNB $16.56
- DMAC $3.96
- Resistance Level
- LCNB $17.04
- DMAC $4.21
- Average True Range (ATR)
- LCNB 0.34
- DMAC 0.18
- MACD
- LCNB -0.01
- DMAC -0.02
- Stochastic Oscillator
- LCNB 71.21
- DMAC 50.00
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.